Table 3. Univariate analyses of survival and local progression free survival for recurrent NPC after IMRT.
| item |
OS |
LPFS |
|||
|---|---|---|---|---|---|
|
|
2-year | P | 2-year | P | |
| Cervical LN | With | 31.1% | 0.087 | 58% | 0.211 |
| Without | 50.7% | 67.4. % | |||
| BED3Gy | ≤116.9 | 48.5% | 0.642 | 59.4% | 0.989 |
| >116.9 | 34% | 65.4% | |||
| rGTV | ≤50ml | 55.4% | 0.031 | 70.3% | 0.125 |
| >50ml | 24.1% | 48.9% | |||
| rPTV | ≤100ml | 66.8% | 0.005 | 82.6% | 0.018 |
| >100ml | 25.1% | 43% | |||
| CRT | no | 52% | 0.334 | 75% | 0.014 |
| yes | 29.3% | 15.6% | |||
| rT stage | rT1-2 | 50% | 0.901 | 58.9% | 0.953 |
| rT3-4 | 54% | 65.9% | |||
| Recurrent stage | Ⅰ-Ⅱ | 57.1% | 0.901 | 54.7% | 0.998 |
| Ⅲ-Ⅳ | 54.8% | 65.6% | |||
| Prestyloid space | no | 55.9% | 0.478 | 48.9% | 0.900 |
| yes | 41.3% | 70.1% | |||
| Poststyloid space | no | 54.9% | 0.022 | 71.2% | 0.072 |
| yes | 36.5% | 59.5% | |||
| Retropharyngeal space | no | 55.8% | 0.062 | 54.5% | 0.799 |
| yes | 32.6% | 67.5% | |||
| Massetric space | no | 43.3% | 0.576 | 71.1% | 0.016 |
| yes | 50% | 20% | |||
| Intracranial cavity | no | 35.5% | 0.136 | 62.7% | 0.899 |
| yes | 56.9% | 66.4% | |||
Abbreviation: CRT= concurrent chemoradiotherapy